About US
Contact us
-
Merck KGaA sees U.S. as 'emerging market' for sales growthAnyone who follows the drug business knows that pharma companies big and not-so-much are aiming for growth in emerging markets. ButMerck KGaAhas a twist on that strategy: The German company sees the U2013/7/1
-
Pfizer, Bristol-Myers tout new VTE data on Eliquis, aiming for new useWhen is non-inferiority actually superior? When you're talking about new substitutes for the difficult-to-administerwarfarin. So, Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) happily announced today2013/7/1
-
Pfizer, Amgen eye $1B deal for Russian biosimilars developer BiocadRussianpharma dealmaking is heating up. On the heels of news thatPharmstandardis shopping its over-the-counter business, thebiosimilardeveloper Biocad is said to be entertaining offers from the likes2013/6/28
-
How to save money via adherence? Let us count the (possible) waysThat there's money to be saved on healthcare spending--and lots of it--is not in question. Exactly how to save that money through further generics use and better prescription adherence is what patient2013/6/28
-
India yanks Takeda's Actos on safety concernsWhy now? That's a fair question aboutIndia'smove to suspend the sale of three drugs, includingTakeda Pharmaceuticals'now-off-patent blockbuster,Actos. The country's health ministry also banned Analgin2013/6/27
-
Bayer, Boehringer eye big growth in expanding anticoagulant marketBlood-clot fighters are expected to grow faster than any other drugs over the next 6 years. Here are two reasons why: The U.K.'s cost-effectiveness watchdog gave final clearance toBayer'santicoagulant2013/6/27
-
Allergan hits skids on probability of early Restasis genericsAllergan is eyeing some earlygeneric competitionfor its $792 million drug Restasis. The FDA says it won't need a clinical trial for approval of copycat versions, meaning the treatment for chronic dry2013/6/26
-
Merck wins Indian injunction against Januvia copycatsMerck's ($MRK)Indianunit won an injunction in a patent fight over its diabetes drugsJanuviaandJanumet, blocking generic versions of the two drugs to be made by Indian drugmaker Aprica Pharmaceuticals.2013/6/26
-
Top-prescribing docs collect cash from drugmakersDoctors who prescribe certain brands the most also have financial ties to the companies that make them, aProPublicainvestigation found. Coincidence? Experts think not. Using Medicare payment data,Pro2013/6/25
-
Eisai pulls Fycompa in Germany to protest pricingEisaiis fed up withGermany'spricing authority. The Japanese drugmaker is so fed up, in fact, that it plans to stop selling its new seizure drug there. It's just the latest example of a pharma company2013/6/25